9Citations
Citations of this article
1Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Introduction. - Oncogenic osteomalacia (OO) is a rare paraneoplastic syndrome characterized by severe hypophosphatemia induced by phosphaturic factors which are secreted by some tumors of mesenchymal origin. Fibroblast Growth Factor 23 (FGF-23) belongs to this family. Measurement of FGF-23 might improve the diagnosis of OO. Exegesis. - We report the case of 71-year-old Caucasian man who had a history of severe osteomalacia with multiples fractures and extreme hypophosphatemia with hyperphosphaturia and normal serum calcium level. Serum FGF-23 was 199 RU/ml (N <100 RU/ml). The tumor, detected by F-18 FDG PET/CT SCAN was localized in the mandible. Surgical removal of the tumor relieved all symptoms with normalization of serum phosphate levels within 3 days after surgery. Conclusion. - We conclude that FGF-23 measurement is likely to be of considerable importance for facilitating early diagnosis of OO. © 2004 Elsevier SAS. Tous droits réservés.

Cite

CITATION STYLE

APA

Dupond, J. L., Magy, N., Mahammedi, M., Prie, D., Gil, H., Meaux-Ruault, N., & Kantelip, B. (2005). L’ostéomalacie oncogène: Rôle des phosphatonines. Intérêt du dosage du fibroblast growth factor 23 démontré chez un malade. Revue de Medecine Interne, 26(3), 238–241. https://doi.org/10.1016/j.revmed.2004.11.013

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free